Drugs & TargetsFree FDA approves Breyanzi in relapsed or refractory large B-cell lymphoma after one prior therapy July 01, 2022Vol.48 No.26
Drugs & TargetsFree EMA CHMP adopts positive opinion for Lynparza in germline BRCA-mutated, HER2-negative high-risk early breast cancer July 01, 2022Vol.48 No.26
Drugs & TargetsFree Community Health Network, GRAIL to offer Galleri MCED test in Central Indiana July 01, 2022Vol.48 No.26
Drugs & TargetsFree FDA issues draft guidance on patient-focused drug development July 01, 2022Vol.48 No.26
Cancer History ProjectFreeObituary Harold Varmus reflects on the life of John Edward Porter, a House appropriator—and his friendPorter helped orchestrate the doubling of the NIH budget between 1998 and 2003 June 24, 2022Vol.48 No.25By Harold Varmus
FreeIn the Archives Survivor Stories: Rob Krigel, Nedra Bonds, Stacey Smith June 24, 2022Vol.48 No.25
FreeObituary Neuroblastoma researcher Robert C. Seeger dies at 82 June 17, 2022Vol.48 No.24By Katherine K. Matthay, Judith G. Villablanca, C. Patrick Reynolds and John M. Maris
FreeIn the Archives Dave Boule confronted polycythemia vera with an accountant’s consistency June 17, 2022Vol.48 No.24
EditorialFree The Cancer Letter receives 7 journalism, design awards June 17, 2022Vol.48 No.24By Katie Goldberg
FreeObituary Moffitt’s Robert Gillies, “father of radiomics,” dies at 69 June 10, 2022Vol.48 No.23By Kim Polacek
